First into Research Fellow, Swansea University
I am a Research and Development lead and Senior Biomedical Scientist within Cellular Pathology in Swansea Bay University Health Board. The research may be tests developed in house or a collaboration with Swansea University. I act as Person Designated (PD), assisting the designated individual (DI) and governance officer ensuring compliance with human tissue authority (HTA) standards for research. I also volunteer on a research ethics committee.
Endometrial cancer (EC) is the most common gynaecological cancer, with over 9,000 new cases diagnosed annually in the UK. Currently divided into two subtypes - Type I (~80% of cases) and Type II [DOI:10.1177/107327480901600102]. This simplistic model has recently been challenged with the development of molecular profiling; however, this too is of limited benefit [DOI:10.1186/s40661-016-0035-4]. There remains a significant need for better profiling of EC to determine and deliver the best patient care pathway.
Genomics can provide a breakthrough solution, leading to a revolutionary understanding into how an individual patient’s cancer has developed, prove instrumental in diagnosing, managing and treating their disease. The focus of my project is to use ‘Spatial transcriptomics’, a ground-breaking technology that enables the measurement of all the gene activity in a tissue sample, mapping this to exactly where the activity is occurring in the tumour.
Applying this to EC samples has the potential to deliver an urgently needed step to change in the care of these patients by enabling personalised therapies to be selected based on gene profiling. This is essential in light of the British Gynaecological Cancer Society COVID-19 guidelines that has put EC as the lowest priority for surgery.